extent of absorption

Forget for a moment how fast a drug gets in — ask instead how much of it ultimately makes it into the bloodstream. That total is the extent of absorption: the cumulative amount of drug that reaches systemic circulation from a dose, regardless of how quickly it got there. Two products can deliver the same total (same extent) at very different speeds (different rate).

Extent is captured by the area under the plasma concentration-time curve (AUC), which sums concentration over time into a measure of total exposure. For a given dose, a larger AUC means more drug was absorbed overall. Extent depends on how completely the drug dissolves and crosses the gut wall and on how much survives first-pass metabolism — so it is intimately tied to bioavailability, of which it is the 'amount' component.

The rate-versus-extent distinction is the backbone of biopharmaceutics assessment. Bioequivalence demands that two products match on extent (AUC) and on rate (Cmax). A formulation change might slow the rate without touching the extent — common and often acceptable in sustained-release design — but a change that reduces the extent means genuinely less drug reaches the body, which is rarely tolerable. Keeping rate and extent conceptually separate prevents serious misreadings of a concentration-time curve.